AlphaQuest LLC Has $1.30 Million Stock Holdings in Day One Biopharmaceuticals, Inc. $DAWN

AlphaQuest LLC raised its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1,065.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 185,006 shares of the company’s stock after purchasing an additional 169,134 shares during the quarter. AlphaQuest LLC owned approximately 0.18% of Day One Biopharmaceuticals worth $1,304,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Royal Bank of Canada boosted its holdings in shares of Day One Biopharmaceuticals by 40.4% in the 1st quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock valued at $1,474,000 after buying an additional 53,459 shares during the last quarter. AQR Capital Management LLC raised its position in Day One Biopharmaceuticals by 601.4% during the first quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock worth $4,906,000 after acquiring an additional 530,429 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Day One Biopharmaceuticals by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock valued at $302,000 after acquiring an additional 2,149 shares during the last quarter. Millennium Management LLC lifted its stake in Day One Biopharmaceuticals by 587.2% in the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock valued at $10,468,000 after acquiring an additional 1,127,995 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock valued at $12,449,000 after acquiring an additional 1,097,679 shares during the period. Institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 15,894 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the sale, the chief executive officer owned 177,165 shares of the company’s stock, valued at approximately $1,578,540.15. The trade was a 8.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Adam Dubow sold 4,319 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the transaction, the insider directly owned 62,626 shares in the company, valued at approximately $557,997.66. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 28,001 shares of company stock worth $249,489 over the last ninety days. Corporate insiders own 6.20% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $11.16 on Monday. Day One Biopharmaceuticals, Inc. has a 12-month low of $5.64 and a 12-month high of $13.20. The business has a 50 day moving average of $9.68 and a 200-day moving average of $8.17. The stock has a market cap of $1.15 billion, a PE ratio of -7.34 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. The business had revenue of $39.80 million during the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The firm’s revenue for the quarter was down 57.6% compared to the same quarter last year. During the same period last year, the firm posted $0.38 EPS. Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. TD Cowen assumed coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Piper Sandler boosted their target price on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.